{"id":"anagliptin-bid-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a DPP-4 inhibitor, anagliptin prevents the degradation of GLP-1 and GIP, incretin hormones that regulate postprandial glucose levels. By extending the half-life of these hormones, anagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release, thereby lowering blood glucose in patients with type 2 diabetes. The BID (twice-daily) dosing regimen optimizes glycemic control throughout the day.","oneSentence":"Anagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:31.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07442006","phase":"PHASE4","title":"Glycemic Variability of Combination Therapies in T2DM","status":"RECRUITING","sponsor":"JW Pharmaceutical","startDate":"2025-10-29","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":178},{"nctId":"NCT04810507","phase":"PHASE4","title":"MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2018-11-09","conditions":"Type 2 Diabetes","enrollment":89},{"nctId":"NCT01529541","phase":"PHASE3","title":"Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":200},{"nctId":"NCT01529528","phase":"PHASE3","title":"A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sitagliptin QD Treatment"],"phase":"marketed","status":"active","brandName":"Anagliptin BID Treatment","genericName":"Anagliptin BID Treatment","companyName":"JW Pharmaceutical","companyId":"jw-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}